FY2024 EPS Estimate for Xeris Biopharma Boosted by Analyst

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Investment analysts at HC Wainwright upped their FY2024 EPS estimates for shares of Xeris Biopharma in a note issued to investors on Monday, November 11th. HC Wainwright analyst O. Livnat now expects that the company will post earnings of ($0.41) per share for the year, up from their previous estimate of ($0.42). HC Wainwright has a “Buy” rating and a $6.60 price objective on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q4 2024 earnings at ($0.07) EPS, FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.03) EPS and FY2028 earnings at $0.51 EPS.

Separately, Piper Sandler cut shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Monday.

Xeris Biopharma Price Performance

NASDAQ:XERS opened at $3.05 on Wednesday. The stock has a market cap of $454.70 million, a PE ratio of -6.78 and a beta of 2.70. Xeris Biopharma has a fifty-two week low of $1.46 and a fifty-two week high of $3.64. The stock’s 50-day moving average is $3.00 and its two-hundred day moving average is $2.53.

Institutional Trading of Xeris Biopharma

A number of institutional investors have recently bought and sold shares of XERS. Vanguard Group Inc. increased its position in Xeris Biopharma by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after purchasing an additional 519,897 shares during the last quarter. Alpine Global Management LLC grew its stake in shares of Xeris Biopharma by 11.1% in the 1st quarter. Alpine Global Management LLC now owns 300,000 shares of the company’s stock valued at $663,000 after buying an additional 30,000 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Xeris Biopharma by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 125,635 shares of the company’s stock worth $278,000 after buying an additional 10,632 shares during the last quarter. NEA Management Company LLC bought a new position in Xeris Biopharma during the first quarter valued at approximately $926,000. Finally, Bayesian Capital Management LP acquired a new stake in Xeris Biopharma in the first quarter valued at approximately $37,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.